Infrastructure grant from the Research Council of Norway: “ATMP Norway – A National Multimodal Infrastructure for ATMP” awarded 74 MNOK

Anna PasettoDirector of ACT
Anna Pasetto
Director of ACT

28 major projects now receive money for new and updated laboratories, equipment, databases and other research infrastructure. In total, the Norwegian Research Council will distribute NOK 1.3 billion. 

"We are excited to announce that the project “ATMP Norway – A National Multimodal Infrastructure for ATMP” has been awarded an infrastructure grant from the Research Council (74 MNOK)", says Anna Pasetto, Director of the Center for Advanced Cell Therapy (ACT) at the Section for Cell Therapy, Division for Cancer Treatment, Oslo University Hospital.

Advanced therapy medicinal products (ATMPs) are medicines for human use that are based on genes, tissues or cells. They offer groundbreaking new opportunities for the treatment of disease and injury.

Oslo University Hospital will invest in new infrastructure to develop medicines based on genes, tissues or cells. This is a field where Norway has a very strong professional environment, but now investments are needed to ensure that we can still be at the forefront. The infrastructure will give academia and industry access to advanced facilities to develop and produce new medicines. This should help to create a better match between the needs of research, industry and the health services.

Links:

Article from the Research Council of Norway 
NOK 1.3 billion for research infrastructure (forskningsradet.no, in Norwegian)

Centre for Advanced Cell Therapy (ACT) home page

The Section of Cellular Therapy

 
Page visits: 1035